Advancing Understanding of Glioblastoma in Underserved Regions
A new narrative review published in 2026 brings together existing studies and regional information to examine how glioblastoma is managed and what neuromarkers are relevant in Sub-Saharan Africa. The work, titled Management and neuromarkers of glioblastoma in Sub-Saharan African: A review of published literature and regional data, highlights the unique obstacles and opportunities in this part of the world.
Glioblastoma, often abbreviated as GBM, is an aggressive form of brain cancer that originates from glial cells. It remains one of the most challenging tumors to treat anywhere, with median survival times typically measured in months even under optimal conditions. Neuromarkers refer to measurable indicators in the nervous system or tumor tissue that can aid diagnosis, prognosis, or treatment selection, such as genetic alterations or protein expressions detectable through imaging or laboratory analysis.
Context of the Publication and Its Authors
The review was authored by Emmanuel O. Oisakede, Oziegbe A. Amhakhian, Odunola F. Atitebi, Omobolaji Rosemary Olasilola, Babajide David Makanjuola, and David B. Olawade. It appears in a peer-reviewed journal accessible via ScienceDirect. Readers can find the full text at https://www.sciencedirect.com/science/article/pii/S2950588726000315. This synthesis arrives at a time when global attention to cancer disparities is growing, particularly for diseases like glioblastoma where outcomes vary sharply by geography and resources.
Sub-Saharan Africa faces distinct hurdles in neuro-oncology. Limited tumor registries mean incidence figures are often estimates rather than precise counts. Diagnostic infrastructure, including advanced imaging and neuropathology expertise, is concentrated in a few urban centers. These factors contribute to later-stage presentations and reduced access to therapies such as temozolomide chemotherapy or tumor-treating fields.
Key Challenges Identified in Regional Literature
Broader scoping reviews of adult brain tumors across Sub-Saharan Africa reveal patterns that apply directly to glioblastoma cases. Western African countries, led by Nigeria, account for the largest share of published studies. Central African nations have contributed fewer papers and often later in time. Most available reports are hospital-based rather than population-level, introducing selection bias toward patients who reach specialized facilities.
Common brain tumors reported in the region include meningiomas alongside glial tumors, yet data on adjuvant treatments and long-term patient outcomes remain sparse. Fewer than 30 studies in one major scoping effort addressed these aspects in detail. Such gaps underscore why a dedicated review focused on glioblastoma management and neuromarkers is timely.
Access to neuro-oncology care involves multiple layers of barriers. Shortages of neurosurgeons and oncologists, combined with high costs for molecular testing, limit routine use of prognostic markers like MGMT promoter methylation status or IDH mutations. Cultural factors, transportation difficulties, and competing health priorities further delay diagnosis for many patients.
Neuromarkers and Their Potential Role in Sub-Saharan Settings
Neuromarkers hold promise for personalizing care, yet their application in resource-limited environments requires adaptation. Standard markers used in high-income settings, such as those guiding decisions on chemotherapy sensitivity, may not be routinely available. The review examines published evidence on which markers have been studied locally and how they correlate with outcomes in African cohorts.
Regional data also point to the need for context-specific research. Environmental exposures, genetic ancestry differences, and infectious disease co-factors prevalent in parts of Sub-Saharan Africa could influence tumor biology and marker expression. Integrating these insights could improve the relevance of future clinical trials conducted on the continent.
Management Strategies and Evidence Gaps
Standard glioblastoma management involves maximal safe surgical resection followed by radiotherapy and chemotherapy. In Sub-Saharan Africa, surgical capacity varies widely. Some centers achieve good resection rates, while others contend with equipment limitations and postoperative care challenges.
The review synthesizes reports on radiotherapy availability, which is often centralized, and chemotherapy access, which can be inconsistent due to supply chains. Supportive care, including management of seizures and edema, forms another critical component discussed in the literature.
Emerging approaches such as targeted therapies or immunotherapy remain largely investigational in the region. The authors highlight opportunities for capacity building through international partnerships and training programs that emphasize both clinical skills and research methodology.
Implications for Researchers and Academic Institutions
Publication of this review serves as a call to action for universities and research centers across Sub-Saharan Africa. It identifies priorities for future studies, including prospective registries, validation of neuromarkers in local populations, and evaluation of cost-effective interventions.
Academic collaboration can accelerate progress. Institutions with strong neurosurgery or oncology departments are well positioned to lead multi-country efforts. Funding agencies and global health organizations increasingly support such initiatives when they address equity in cancer outcomes.
For early-career researchers, topics like glioblastoma in low-resource settings offer meaningful avenues for impactful work. Training in biobanking, molecular diagnostics, and clinical trial design tailored to regional needs represents a growing area of demand.
Photo by Bhautik Patel on Unsplash
Future Outlook and Opportunities
Continued synthesis of regional data will be essential as diagnostic capabilities expand. Portable imaging, telepathology, and point-of-care biomarker assays could narrow gaps. The review provides a foundation for these developments by cataloging what is already known and where evidence is thin.
Policy recommendations emerging from such work often emphasize integration of neuro-oncology into national cancer control plans. Strengthening referral networks and investing in workforce development are recurring themes in related literature on brain tumor care in Africa.
International databases and open-access platforms can amplify the visibility of African-led research. This helps counter historical underrepresentation in global neuro-oncology literature.
Practical Steps for Stakeholders
Clinicians can use the review to benchmark current practices against available evidence. Researchers may identify collaborators or data sources for new projects. Administrators at teaching hospitals can advocate for equipment and training aligned with identified needs.
Patients and families benefit indirectly through improved guidelines that reflect regional realities rather than solely high-income country protocols. Advocacy groups focused on brain tumors can draw on the synthesized findings to raise awareness and push for resources.